info@seagull-health.com
SeagullHealth
search
Dacomitinib(Vizimpro)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Dacomitinib(Vizimpro) Instructions:Uses,Dosage, Side Effects
VIZIMPRO (dacomitinib) is an oral kinase inhibitor approved for the treatment of metastatic non-small cell lung cancer with specific EGFR mutations.
VIZIMPRO is a prescription medication classified as a kinase inhibitor, used primarily in the first-line treatment of metastatic non-small cell lung cancer (NSCLC). It targets tumors with EGFR exon 19 deletions or exon 21 L858R mutations, as identified by an FDA-approved test. The drug comes in tablet form and was initially approved in the U.S. in 2018.
VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
The recommended dosage is 45 mg taken orally once daily, with or without food. Treatment should continue until disease progression or unacceptable toxicity occurs. Dose reductions to 30 mg and then to 15 mg are recommended for management of specific adverse reactions. Avoid concomitant use with proton pump inhibitors (PPIs).
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
